Milciclib - CAS 802539-81-7
Catalog number: 802539-81-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
CDK
Description:
Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
Light yellow to yellow solid
Synonyms:
PHA-848125; PHA848125; PHA 848125; PHA-848125AC; PHA 848125AC; PHA848125AC
MSDS:
Inquire
Current Developer:
Nerviano Medical Sciences.
1.Epidemiological Surveillance of Leishmaniasis in Montenegro, 1992-2013.
Medenica S, Jovanović S, Dožić I, Milicić B, Lakićević N, Rakocević B. Srp Arh Celok Lek. 2015 Nov-Dec;143(11-12):707-11.
INTRODUCTION: The diseases caused by Leishmania are spread worldwide and represent a significant public health problem.
2.INTRAOPERATIVE ANEURYSMAL RUPTURE: CLINICAL OUTCOME FOLLOWING OPEN SURGERY OR ENDOVASCULAR TREATMENT.
Lakićević N, Prstojević B, Rasulić L, Vujotić L, Vukašinović Ivan, Miličić B, Savić A, Živković B, Rotim K, Samardžić M. Acta Clin Croat. 2015 Sep;54(3):285-94.
The aim of this study was to evaluate and compare the outcomes of intraoperative aneurysmal rupture in patients with subarachnoid hemorrhage undergoing open surgical or endovascular treatment. This retrospective study included 742 patients with aneurysmal subarachnoid hemorrhage treated at the Clinical Department of Neurosurgery, Clinical Center of Serbia, during a three-year period. Among them, 167 (31.15%) were treated by clipping and 33 (16.01%) by coiling in the early phase (≤72 hours). The overall outcome and pretreatment variables were analyzed for each group, including between-group difference according to the occurrence of intraoperative aneurysmal rupture. Intraoperative aneurysmal rupture occurred in 14.7% of microsurgical and 2.4% of endovascular procedures. It was more frequent in early procedures as compared with delayed procedures (27.5% and 9.7% vs. 2.2% and 1.1%, respectively). On the contrary, mortality rates were lower in the surgical group (11.
3.Analysis of cervical resistance during continuous controllable balloon dilatation: controlled clinical and experimental study.
Arsenijevic P1, Milosevic M2, Zivanovic A3, Milicic B4, Jeremic B5, Filipovic N6, Protrka Z7, Todorovic P8, Arsenijevic S9. Trials. 2015 Oct 28;16:485. doi: 10.1186/s13063-015-1003-8.
BACKGROUND: Hydraulic dilatation is a novel method of cervical dilatation that is based on continuous controllable dilatation (CCBD) by the pumping of fluid into the balloon extension of the system. The main advantage of this procedure is that it allows control of and insight into the process of cervical dilatation.
4.Impact of the lower third molar and injury mechanism on the risk of mandibular angle and condylar fractures.
Antic S1,2, Milicic B3,4, Jelovac DB5, Djuric M2. Dent Traumatol. 2016 Jan 28. doi: 10.1111/edt.12259. [Epub ahead of print]
BACKGROUND: Previous studies have shown the influence of the mandibular third molar on mandibular angle and condylar fractures, but have not comparatively analyzed the impact of the injury mechanism on these fractures. The purpose of this study was to evaluate the influence of the lower third molar (M3) and injury-related factors (fracture etiology and site of impact of the traumatic force) on the risk of mandibular angle and condylar fractures.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


CGP74514A
(CAS: 190653-73-7)

CGP74514A is a cell permeable Cdk inhibitor selective for Cyclin-dependent kinase-1 (Cdk1) (IC50=25nM). CGP74514A was also reported also to affect the activitie...

LOR-253
(CAS: 916151-99-0)

LOR-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) mast...

CAS 199986-75-9 CVT-313

CVT-313
(CAS: 199986-75-9)

A cell-permeable purine analog that acts as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk2 (IC50 = 0.5 µM for Cdk2/A and Cdk2/E; 4.2 µM ...

CAS 602306-29-6 AZD5438

AZD5438
(CAS: 602306-29-6)

AZD5438 is a potent inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC(50), 16, 6, and 20 nmol/L, respectively). Broad cdk inhibition may provide an eff...

CAS 872573-93-8 RO-3306

RO-3306
(CAS: 872573-93-8)

RO-3306 is a CDK1 inhibitor with potential anticancer activity. Treatment of growing AML cells with RO-3306 induced G2/M-phase cell cycle arrest and apoptosis ...

CAS 784210-87-3 RGB-286638

RGB-286638
(CAS: 784210-87-3)

RGB-286638 is a novel CDK inhibitor. It inhibited several tyrosine and serine/threonine non-CDK enzymes, i.e. GSK-3β, TAK1, AMPK, Jak2, MEK1. It demonstrated eq...

KH-CB19
(CAS: 1354037-26-5)

KH-CB19, a CLK1/CLK4 inhibitor, has been found to probably restrain the phosphorylation of serine- and arginine-rich (SR) proteins. IC50: 20 nM for CLK1.

ON123300
(CAS: 1357470-29-1)

ON123300, a dihydropyrido[2,3-d]pyrimidine derivative, has been found to be an effective multikinase inhibitor that could be probably used against brain tumor a...

CAS 345627-80-7 SNS-032

SNS-032
(CAS: 345627-80-7)

SNS-032, also known as BMS-387032, is a 2-aminothiazole-derived, small-molecule cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. ...

CAS 212844-53-6 Purvalanol A

Purvalanol A
(CAS: 212844-53-6)

Purvalanol A is a potent CDK inhibitor, which effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. indicating that the activati...

CAS 1604810-83-4 THZ1

THZ1
(CAS: 1604810-83-4)

THZ1 is a selective CDK7 inhibitor that preferentially diminishes transcription in cancer cells. THZ1 has the unprecedented ability to target a remote cysteine ...

CAS 496864-16-5 Aloisine A

Aloisine A
(CAS: 496864-16-5)

Aloisine a is a cell-permeable pyrrolo-pyrazine compound that acts as a potent, selective, reversible, and ATP-competitive inhibitor of cyclin dependent kinases...

CAS 1414943-88-6 BAY-1143572

BAY-1143572
(CAS: 1414943-88-6)

BAY 1143572 is a highly selective, potent and orally available inhibitor ofPTEFb/CDK9 and shows convincing anti-tumor activity in multiple xenograft models by t...

CAS 211555-08-7 WHI-P180

WHI-P180
(CAS: 211555-08-7)

WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i...

CAS 844442-38-2 AT-7519

AT-7519
(CAS: 844442-38-2)

AT-7519 is an orally bioavailable small molecule CDK inhibitor with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependen...

CAS 1204918-72-8 SB1317

SB1317
(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

CAS 902156-99-4 NVP-LCQ195

NVP-LCQ195
(CAS: 902156-99-4)

NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5. It induced cell cycle arrest and eventual apoptotic cell death of MM cells, ...

CAS 942425-68-5 PHA-767491 hydrochloride

PHA-767491 hydrochloride
(CAS: 942425-68-5)

PHA-767491 hydrochloride is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor, which prevents initiation of DNA replication. It inhibits cell proliferation in ...

CAS 1883423-59-3 MSC2530818

MSC2530818
(CAS: 1883423-59-3)

MSC2530818 is a specific and orally available CDK8 Inhibitor with an IC50 of 2.6 nM for CDK8.

AU-12122

AU-12122 is a novel-developed CDK7 inhibitor, which is potent and orally bioactive. It induces apoptosis of acute monocytic leukemia THP-1.

Chemical Structure

CAS 802539-81-7 Milciclib

Quick Inquiry

Verification code

Featured Items